At the time of writing, Taysha Gene Therapies Inc [TSHA] stock is trading at $3.26, up 12.41%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TSHA shares have gain 9.76% over the last week, with a monthly amount glided 18.98%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Taysha Gene Therapies Inc [NASDAQ: TSHA] stock has seen the most recent analyst activity on July 11, 2025, when BofA Securities initiated its Buy rating and assigned the stock a price target of $8. Previously, BMO Capital Markets started tracking the stock with Outperform rating on June 27, 2024, and set its price target to $5. On April 09, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $9 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $1.50 on February 01, 2023. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $3 on January 27, 2023. Goldman downgraded its rating to Neutral for this stock on November 09, 2022, and downed its price target to $3. In a note dated March 09, 2022, Robert W. Baird initiated an Outperform rating and provided a target price of $26 on this stock.
For the past year, the stock price of Taysha Gene Therapies Inc fluctuated between $1.05 and $3.31. Currently, Wall Street analysts expect the stock to reach $18.67 within the next 12 months. Taysha Gene Therapies Inc [NASDAQ: TSHA] shares were valued at $3.26 at the most recent close of the market. An investor can expect a potential return of 472.7% based on the average TSHA price forecast.
Analyzing the TSHA fundamentals
According to Taysha Gene Therapies Inc [NASDAQ:TSHA], the company’s sales were 8.10M for trailing twelve months, which represents an 78.60% jump. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -11.61%, Pretax Profit Margin comes in at -11.45%, and Net Profit Margin reading is -11.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.8 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.02 points at the first support level, and at 2.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.39, and for the 2nd resistance point, it is at 3.52.
Ratios To Look Out For
It is important to note that Taysha Gene Therapies Inc [NASDAQ:TSHA] has a current ratio of 12.48. Also, the Quick Ratio is 12.48, while the Cash Ratio stands at 12.34. Considering the valuation of this stock, the price to sales ratio is 109.79, the price to book ratio is 3.57.
Transactions by insiders
Recent insider trading involved Nagendran Sukumar, President and Head of R&D, that happened on Aug 21 ’25 when 57054.0 shares were sold. CHIEF FINANCIAL OFFICER, Alam Kamran completed a deal on Aug 21 ’25 to sell 54491.0 shares. Meanwhile, Officer Kamran Alam bought 54491.0 shares on Aug 21 ’25.
